The observed outcomes suggest that the combination of (i) CHOP plus rituximab and (ii) radiotherapy for local recurrence prophylaxis is promising for both stage I-II and stage III-IV PTL.
Acute myeloid leukemia (AML) with
BCR-ABL1
is rare and has a poor prognosis with conventional chemotherapy or
ABL
tyrosine kinase inhibitors (TKIs) alone. We reported a case of AML with
BCR-ABL1
patient who was successfully treated with dasatinib alone; additionally, we previously reported another case of long-term remission maintained with imatinib monotherapy. These results suggested that a treatment with a novel and significantly potent TKI may be effective in AML with
BCR-ABL1
patients with low tumor burden and without additional chromosome aberrations and
ABL
kinase domain mutations.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.